POHMS wants to thank our corporate sponsors. With your support we are able to fulfill the mission of this organization which is to improve the business conditions of the hematology oncology practice.
Please see information below for 2023 Corporate Sponsorship:
Diamond Level ($12,000/year): includes four (4) company representatives, POHMS Newsletter, preferred exhibit space, live drug announcements, active link on POHMS website, and exhibits of no extra charge at POHMS Spring and Fall Conferences. Specific to the Diamond Level only: membership directory AND time in front of the POHMS Board of Directors and POHMS members once a year (see details on Corporate Sponsor letter) upon request.
Gold Level ($9,500/year): includes three (3) company representatives, POHMS Newsletter, preferred exhibit space, live drug announcements, active link on POHMS website, and exhibits of no extra charge at POHMS Spring and Fall Conferences
Silver Level ($5,000/year): includes two (2) company representatives, POHMS Newsletter, preferred exhibit space, live drug announcements, active link on POHMS website, and discounted exhibits at POHMS Spring and Fall Conferences
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit our website and follow us on Twitter at @BeiGeneUSA.Learn More
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.Learn More
CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.
CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices. CHOC's current preferred vendor is McKesson Specialty Health.
CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.
CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.Learn More
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, click here.Learn More
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan.
For more information, click here and follow @Incyte.Learn More
McKesson empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our community oncology practice customers and help them provide quality care for patients.Learn More
We’re proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer. We’re continuing to accelerate what we can achieve for the patients we serve, because everyone needs more ways to treat their cancer and, hopefully, more time. We’re working to invent a world where cancer isn’t just treated, but cured.Learn More
Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. MorphoSys is currently headquartered in Planegg, Germany. In 2019, the US head office was established in BostonLearn More
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.Learn More
Sanofi Oncology, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
CareASSIST® – Patient Support by Sanofi
CareASSIST is committed to helping remove barriers for eligible patients and caregivers throughout their treatment journey. We consider it our mission to deliver reliable access and financial assistance to eligible patients prescribed Sanofi oncology medications. Our Care Managers are available to answer questions, provide more information, and support patients and providers every step of the way.
Questions? We’re here to help. To learn more about the CareASSIST program and additional support options, please contact a dedicated Care Manager at 1-833-WE+CARE (1-833-930-2273), Mon – Fri, 9 AM – 8 PM ET, or visit our website at SanofiCareASSIST.com.
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.Learn More
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.
We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.
Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.
Our purpose is to re-imagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
For more information about Pharmacyclics LLC, an AbbVie Company, click here
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization.Learn More
TAKEDA ONCOLOGY (formerly known as MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY) endeavors to deliver novel medicines to cancer patients worldwide through our science, innovation and passion for improving patients’ lives. We know this mission is not an easy one but we are up to the task: we aspire to cure cancer.
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. With the acquisitions of Pharmacyclics in 2015 and Stemcentrx in 2016, our research and development efforts, and through collaborations, AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 200 clinical trials and more than 20 different tumor types. For more information, click here.Learn More
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.Learn More
Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created Changing Tomorrow Day, an annual, worldwide volunteer event, to demonstrate this commitment.Learn More
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care.Learn More
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more: click hereLearn More